Protective Efficacy of a Human Endogenous Retrovirus Envelope-Coated,Nonreplicable, Baculovirus-Based Hemagglutin Vaccine against PandemicInfluenza H1N1 2009

Collection with item attached
2013
Item details URL
http://open-repository.kisti.re.kr/cube/handle/open_repository/483709.do
DOI
10.1371/journal.pone.0080762
Title
Protective Efficacy of a Human Endogenous Retrovirus Envelope-Coated,Nonreplicable, Baculovirus-Based Hemagglutin Vaccine against PandemicInfluenza H1N1 2009
Description
This research was supported by Top Brand Project grant from KoreaResearch Council of Fundamental Science & Technology and KRIBBInitiative program (NTM1311322), by iPET from Ministry of Agriculture,Food and Rural Affairs (112157-03-1-SB020, 112138-03-1-SB030, and110082-03-2-SD010), by Konkuk University (Center for Glocal DiseaseControl). The funders had no role in study design, data collection andanalysis, decision to publish, or preparation of the manuscript.
abstract
Despite the advantages of DNA vaccines, overcoming their lower efficacy relative to that of conventional vaccines remains a challenge. Here, we constructed a human endogenous retrovirus (HERV) envelope-coated, nonreplicable, baculovirus-based HA vaccine against swine influenza A/California/04/2009(H1N1) hemagglutin (HA) (AcHERV-sH1N1-HA) as an alternative to conventional vaccines and evaluated its efficacy in two strains of mice, BALB/c and C57BL/6. A commercially available, killed virus vaccine was used as a positive control. Mice were intramuscularly administered AcHERV-sH1N1-HA or the commercial vaccine and subsequently given two booster injections. Compared with the commercial vaccine, AcHERV-sH1N1-HA induced significantly higher levels of cellular immune responses in both BALB/c and C57BL/6 mice. Unlike cellular immune responses, humoral immune responses depended on the strain of mice. Following immunization with AcHERV-sH1N1-HA, C57BL/6 mice showed HA-specific IgG titers 10- to 100-fold lower than those of BALB/c mice. In line with the different levels of humoral immune responses, the survival of immunized mice after intranasal challenge with sH1N1 virus (A/California/04/2009) depended on the strain. After challenge with 10-times the median lethal dose (MLD50) of sH1N1 virus, 100% of BALB/c mice immunized with the commercial vaccine or AcHERV-sH1N1-HA survived. In contrast, C57BL/6 mice immunized with AcHERV-sH1N1-HA or the commercial vaccine showed 60% and 70% survival respectively, after challenge with sH1N1 virus. In all mice, virus titers and results of histological analyses of lung tissues were consistent with the survival data. Our results indicate the importance of humoral immune response as a major defense system against influenza viral infection. Moreover, the complete survival of BALB/c mice immunized with AcHERV-sH1N1-HA after challenge with sH1N1 virus suggests the potential of baculoviral vector-based vaccines to achieve an efficacy comparable to
provenance
Made available in Cube on 2018-09-28T14:54:05Z (GMT). No. of bitstreams: 0
language
English
author
Choi, Jae-Yoo
Gwon, Yong-Dae
Kim, Jeong-Ki
Cho, Yeon-Dong
Heo, Yoon-Ki
Cho, Han-Sam
Choi, Tae-Jin
Poo, Ha-Ryoung
Oh, Yu-Kyoung
Kim, Young Bong
orcid
Gwon, Yong-Dae/0000-0002-0703-4188
accessioned
2018-09-28T14:54:05Z
available
2018-09-28T14:54:05Z
issued
2013
citation
PLOS ONE(8): 11
issn
1932-6203
uri
http://open-repository.kisti.re.kr/cube/handle/open_repository/483709.do
Funder
해양수산부
Funding Program
수산실용화기술개발사업
Project ID
1525003160
Jurisdiction
Rep.of Korea
Project Name
비증식성 나노수송체를 이용한 새우 흰반점 바이러스 (WSSV)에 대한 유전자 백신 개발
rights
openAccess
type
article


Files in This Item

There are no attached files.